Schizophrenia  >>  Invega Sustenna (paliperidone palmitate extended-release 1-month injection)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
NCT01181960: Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Completed
N/A
1066
US
Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts
Janssen Scientific Affairs, LLC
Schizophrenia, Bipolar Disorder
11/13
11/13
NCT01359293: Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures

Recruiting
N/A
120
US
paliperidone palmitate, Sustenna, oral antipsychotics
University of Iowa, Wishard Health Services
Schizophrenia, Schizophreniform
04/14
12/14
NCT01698216: Switching From Consta® to Sustenna® in Patients With Schizophrenia

Completed
N/A
50
RoW
Seoul National University Hospital
Schizophrenia
05/15
05/15

Download Options